Lead Product(s) : Piromelatine
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 04, 2022
Lead Product(s) : Piromelatine
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TEV-50717
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Nuvelution TS Pharma, Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 02, 2018
Lead Product(s) : TEV-50717
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Nuvelution TS Pharma, Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pramipexole Dihydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 24, 2013
Lead Product(s) : Pramipexole Dihydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable